| AdnaGen AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20110236904 | DETECTION OF TUMOR STEM CELLS AND TUMOR CELLS IN EPITHELIAL-MESENCHYMAL TRANSITION IN BODY FLUIDS OF CANCER PATIENTS - The present invention relates to the detection of tumor stem cells and tumor cells in epithelial-mesenchymal transition and uses of such methods. | 09-29-2011 |
| 20100285581 | Solid Phase Cell Isolation and/or Enrichment Method - The present invention concerns a solid phase method for isolating and/or enriching predetermined cells from a sample. Such methods are used e.g. to isolate and enrich predetermined cells like fetal cells from a sample of maternal peripheral blood, tumor cells from a sample of body fluid or stem cells from a fluid or fluidized sample of body tissue or body fluid. The solid phase isolation method of the present invention is used for isolating predetermined cells from a sample containing such predetermined cells by binding the predetermined cells to a solid surface. According to the invention the sample is contacted with the solid surface and then removed from the solid surface, wherein the sample or a washing buffer contains a polyol during or after contacting the sample with the solid surface. | 11-11-2010 |
| 20100159445 | METHOD FOR THE INDIVIDUAL STAGING OF TUMOR DISEASES - The present invention concerns a method for the individual staging of the tumor disease of an individual cancer patient, a method for the individual decision on the method of treatment as well as a method for treating a cancer patient as well as their use in the treatment of various cancer diseases like colorectal tumor, prostate tumor, breast tumor, lung tumor, as primary tumors, tumor relapse and/or metastases. The present invention further provides a new prognosis factor in cancer treatment. This inventive method includes the step of analyzing at least one disseminated tumor cell present in a sample taken from a patient for the expression of at least one mRNA of at least one of growth factors, growth factor receptors and tumor associated transcripts. | 06-24-2010 |
| 20080305480 | NOVEL TUMOR MARKER - The present invention concerns a gene product largely homologous to the epithelial growth factor receptor (EGFR). It further refers to mRNA coding for such epithelial growth factor receptor. The present invention provides such an epithelial growth factor receptor which is characterized in that either exons 12 to 14 or exons 12 to 15 are deleted. These novel variants of the epithelial growth factor receptor can be used for a diagnosis, stratification, therapy guidance of a tumor or therapy guidance of tumor surgery. | 12-11-2008 |
